Overview
Intersect ENT is a global ear, nose and throat medical technology leader dedicated to transforming patient care. The Company's steroid releasing implants are designed to provide mechanical spacing and deliver targeted therapy to the site of disease. In addition, Intersect ENT is continuing to expand its portfolio of products based on the Company's unique localized steroid releasing technology and is committed to broadening patient access to less invasive and more cost-effective care. In October 2020, Intersect ENT acquired Fiagon AG Medical Technologies, a global leader in electromagnetic surgical navigation solutions with an expansive portfolio of ENT product offerings, including the VENSURE sinus balloon, that complement the Company's PROPEL® and SINUVA® sinus implants and extend its geographic reach.
Basic Stats
The share price of Intersect ENT Inc as of May 12, 2022 is $28.24 / share.
The Factor Analysis chart (below right) shows a view of Intersect ENT Inc from a variety of lenses. Each factor shows how well the company ranks against all other companies in the Fintel global investing universe. Factor scores range from zero to 100, with 100 being most desirable, and 50 being average.
For example, a company with a Value Score of 100 would be the most undervalued company in our database. A company with a Value Score of zero would be the most overvalued.
| Market Cap | |
| EV | |
| Shares Out. | |
| Earnings Date | |
| EPS (TTM) | |
| Dividend Yield | |
| Ex-Dividend Date | |
| Borrow Rate | |
| Short Shares Avail. | |
| Short Interest | |
| Short Float | |
| Days to Cover | |
| Risk Free Rate | 4.17 % |
| Price Change (1 yr) | |
| Volatility (1 yr) | |
| Beta | |
| Sharpe Ratio (1 yr) | |
| Sortino Ratio (1 yr) |
| PE Ratio | |
| Price/Book | |
| Price/TBV | |
| Book/Market | |
| EBIT/EV | |
| EBIT(3yr avg)/EV | |
| ROA | |
| ROE | |
| ROIC | |
| CROIC | |
| OCROIC | |
| Implied Volatility | |
| Put/Call OI Ratio |
| Growth | |
| Profitability | |
| Quality Score | |
| Value Score | |
| Momentum Score | |
| Stability (Low Vol) Score | |
| Analyst Sentiment | |
| Fund Sentiment | |
| Insider Sentiment | |
| Officer Sentiment | |
| Dividend Score | |
| QVM Score | |
| Piotroski F-SCORE |
Factor Scores range from 0 to 100, with 100 being most desirable. Larger circles are better. In situations where we have no data (e.g. no insider trades), we plot the score at 50 to avoid penalizing companies. However, a company that does not pay dividends will get a Dividend Score of Zero. Additionally, we inverted volatility to create a "stability" metric which is better when higher.
Price Target
The average one-year price target for Intersect ENT Inc is $28.82. The forecasts range from a low of $28.53 to a high of $29.66. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. Analysts typically set price targets that correspond to their buy or sell recommendations.
Update Frequency: Monthly
| Record Date | Projection Date | High | Low | Median | Average |
|---|---|---|---|---|---|
| 2023-03-27 | 2024-03-27 | 29.66 | 28.53 | 28.82 | 28.82 |
Stock Upgrades/Downgrades
This card shows analyst upgrades/downgrades for Intersect ENT Inc. An analyst rating is a classification that gives investors a sense of analyst sentiment about the direction and performance of an equity - usually a stock - over a period of time, typically 12 months.
The standard analyst ratings are generally as follows:
- Buy/Overweight/Outperform - Any of these ratings conveys an analyst’s belief that the stock is likely to outperform a market index (e.g. the S&P 500).
- Hold/Equal-Weight/Market Perform - Any of these ratings conveys an analyst’s belief that the stock is likely to perform in line with a market index.
- Sell/Underweight/Underperform - Any of these ratings suggest that an analyst believes the stock is likely to underperform a market index.
When an analyst upgrades a stock, they are signaling that the company’s fundamentals are being undervalued by investors. It could also mean they believe the market is underestimating the company’s potential. The opposite is true when a stock receives a downgrade.
The average rating of each individual analyst’s rating is the consensus rating for a stock. This gives investors a broader sense of the overall sentiment for that stock.
| Date | Analyst | Prior | Latest Recommendation |
Action |
|---|---|---|---|---|
| 2021-08-12 | SVB Leerink | Outperform | Market Perform | Downgrade |
| 2021-08-10 | BTIG | Buy | Neutral | Downgrade |
| 2021-08-09 | Guggenheim | Buy | Neutral | Downgrade |
| 2021-08-09 | Canaccord Genuity | Buy | Hold | Downgrade |
| 2021-06-24 | SVB Leerink | Market Perform | Outperform | Upgrade |
| 2021-05-11 | SVB Leerink | Market Perform | Maintains | |
| 2021-03-10 | SVB Leerink | Market Perform | Maintains | |
| 2021-01-11 | Canaccord Genuity | Hold | Buy | Upgrade |
| 2020-12-03 | SVB Leerink | Market Perform | Maintains | |
| 2020-11-19 | BTIG | Neutral | Buy | Upgrade |
| 2020-11-03 | SVB Leerink | Market Perform | Maintains | |
| 2020-10-08 | JP Morgan | Overweight | Neutral | Downgrade |
| 2020-08-05 | SVB Leerink | Market Perform | Maintains | |
| 2020-07-15 | SVB Leerink | Market Perform | Maintains | |
| 2020-06-29 | SVB Leerink | Market Perform | Maintains | |
| 2020-06-24 | Oppenheimer | Perform | Initiate | |
| 2020-05-12 | SVB Leerink | Market Perform | Maintains | |
| 2020-05-12 | JP Morgan | Overweight | Maintains | |
| 2020-05-12 | Canaccord Genuity | Buy | Hold | Downgrade |
| 2020-04-15 | B of A Securities | Buy | Underperform | Downgrade |
| 2019-12-20 | JP Morgan | Overweight | Maintains | |
| 2019-08-02 | Piper Jaffray | Overweight | Neutral | Downgrade |
| 2019-08-02 | Guggenheim | Buy | Neutral | Downgrade |
| 2019-07-10 | Northland Securities | Underperform | Market Perform | Upgrade |
| 2019-06-21 | Berenberg | Buy | Hold | Downgrade |
| 2019-05-07 | SVB Leerink | Outperform | Market Perform | Downgrade |
| 2019-05-07 | Northland | Market Perform | Underperform | Downgrade |
| 2019-02-26 | Canaccord Genuity | Buy | Buy | Maintains |
| 2018-01-02 | JP Morgan | Neutral | Overweight | Upgrade |
| 2017-09-13 | Canaccord Genuity | Buy | Maintains | |
| 2017-08-02 | Deutsche Bank | Buy | Maintains | |
| 2017-05-31 | Northland Securities | Outperform | Market Perform | Downgrade |
| 2017-03-06 | Deutsche Bank | Hold | Buy | Upgrade |
| 2016-12-07 | Guggenheim | Buy | Initiate | |
| 2016-11-02 | JP Morgan | Overweight | Neutral | Downgrade |
| 2016-10-06 | Deutsche Bank | Hold | Initiate | |
| 2016-03-29 | Northland Securities | Outperform | Initiate | |
| 2015-12-18 | Bank of America | Buy | Initiate | |
| 2015-11-05 | Leerink Swann | Outperform | Maintains | |
| 2015-09-29 | PiperJaffray | Overweight | Maintains | |
| 2015-06-30 | Cantor Fitzgerald | Buy | Initiate | |
| 2015-06-17 | Leerink Swann | Outperform | Maintains | |
| 2015-06-09 | Canaccord Genuity | Buy | Maintains | |
| 2015-05-07 | Leerink Swann | Outperform | Maintains | |
| 2015-04-09 | CRT Capital | Buy | Initiate | |
| 2015-03-16 | Canaccord Genuity | Buy | Initiate | |
| 2014-08-18 | PiperJaffray | Overweight | Initiate | |
| 2014-08-18 | Leerink Swann | Outperform | Initiate | |
| 2014-08-18 | JP Morgan | Overweight | Initiate |
